Title : Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Post-Switch to Dolutegravir and Rilpivirine in SWORD-1/-2.

Pub. Date : 2022 May 13

PMID : 35551149






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Through Week 48, changes in biomarkers did not significantly differ between dolutegravir + rilpivirine and CAR groups, except for increases in soluble CD14 and decreases in fatty acid binding protein-2, which favored dolutegravir + rilpivirine. dolutegravir fatty acid binding protein 2 Homo sapiens